(1) Abeloff, M.D., Armitage, J.O., Lichter, A.S. & Niederhuber, J.E. (2000). Clinical Oncology. Second edition. Churchill Livingstone. Edinburgh.
(2) Hanahan, D. & Weinberg, R.A. (2000). The Hallmarks of Cancer. Cell. 100, 57-70.
(3) Bertram, J.S. (2001). The Molecular Biology of Cancer. Mol Aspect Med. 21, 167- 223.
(4) Spencer, S.L., Berryman, M.J., Garcia, J.A. & Abbott, D. (2004). An ordinary differencial equation model for the multistep transformation to cancer. J Theor Biol.
231, 515-524.
(5) Gilligan, T.D., Steele, G.S., Zietman, A.L. & Kantoff, P.W. (2003). Bladder Cancer. In Kufe, D.W., Pollock, R.E., Weichselbaum, R.R., Bast Jr., R.C., Gansler, T.S., Holland, J.F. & Frei, E., Cancer Medicine. Sixth edition. B.C. Decker Inc. Hamilton.
(6) Cooper, G.G. (2000). The Cell – A Molecular Approach. Second Edition. ASM Press.
Washington, D.C.
(7) DeVita, V.T., Hellman, S. & Rosenberg, S.A. (2000). Cancer Principles & Practice of Oncology. Sixth edition. Lippincott. Philadelphia.
(8) Lodish, H., Berk, A., Zipursky, S.L., Matsudaisra, P., Baltimore, D. & Darnell, J.
(2000). Molecular Cell Biology. Fourth edition. W. H. Freeman and Company. New York.
(9) Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J. & Thun, M.J. (2007) Cancer Statistics, 2007. CA Cancer J Clin. 57, 43-66.
(10) Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., Smigal, C. & Thun, M.J.
(2006) Cancer Statistics, 2006. CA Cancer J Clin. 56, 106-130.
(11) Instituto Nacional de Estatística. Óbitos por causa de morte, segundo a idade e o sexo (Portugal 2006). Disponível em: http://www.ine.pt
(12) Pinheiro, P.S., Tyczynski, J.E., Bray, F., Amado, J., Matos, E. & Parkin, D.M.
(2003). Cancer incidence and mortality in Portugal. Eur J Cancer. 39, 2507-2520.
(13) Algaba, F. & Trias, I. (2000). Morfobiología de las neoplasias superficiales de la vejiga urinaria. In Vicent, J., Chechile, G. & Salvador, J., Tumores vesicales superficiales. Edita Acción Médica, SA. Madrid.
(14) Young, B. & Heath, J.W. (2000). Wheater’s Functional Histology – A Text and Colour Atlas. Fourth edition. Churchill Livingstone. Edinburgh.
(15) Junqueira, L.C. & Carneiro, J. (2004). Histologia Básica. Décima edição.
Guanabara Koogan. Rio de Janeiro.
BIBLIOGRAFIA 192
(16) Wu, X. (2005). Urothelial Tumorigenesis: a tale of divergent pathways. Nat Rev Cancer. 5, 713-725.
(17) Johansson, S.L. & Coihen, S.M. (1997). Epidemiology and Ethiology of Bladder Cancer. Semin Surg Oncol. 13,291-298.
(18) Redman, B.G., Kawachi, M. & Hurwitz, M. (2005). Urothelial and Kidney Cancer.
In Pazdur, R., Coia, L.R., Hoskins, W.J. & Wagman, L.D., Cancer Management – A Multidisciplinary Approach. Ninth edition. CMP Healthcare Media. New York.
(19) Reuter, V.E. (2006). The Pathology of Bladder Cancer. Urology. 67(3A), 11-18.
(20) Koss, L.G. (1992). Bladder cancer from a perspective of 40 years. J Cell Biochem Suppl. 161, 23-29.
(21) Spiess, P.E. & Czerniak, B. (2006). Dual-track Pathway in Bladder Carcinogenesis.
Arch Pathol Lab Med. 130, 844-852.
(22) Knowles, M.A. (2005). Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese? Carcinogenesis. 27(3), 361-373.
(23) Williams, S.G. & Stein J.P. (2004). Molecular Pathways in Bladder Cancer. Urol Research. 32(6), 373-385.
(24) Kausch, I. & Böhle, A. (2002). Molecular Aspects of Bladder Cancer III. Prognostic Markers of Bladder Cancer. Eur Urol. 41, 15-29.
(25) Baffa, R., Letko, J., McClung, C., Lenoir, J., Vecchione, A. & Gomella, L.G.
(2006). Molecular genetics of bladder cancer: targets for diagnosis and therapy. J Exp Clin Cancer Res. 25(2), 145-160.
(26) Orntoft, T.F., Zieger, K. & Dyrskjot, L. (2006). Recent developments in molecular profiling of bladder cancer. Curr Opin Urol. 16(5), 377-381.
(27) Lianes, P. (2000). Biologia molecular del cáncer de vejiga. In Vicent, J., Chechile, G. & Salvador, J., Tumores vesicales superficiales. Edita Acción Médica, SA.
Madrid.
(28) Santos, L. (2003). Aspectos Moleculares na Progressão do Carcinoma Urotelial da Bexiga. Tese de Doutoramento. Faculdade de Medicina da Universidade do Porto.
(29) Jerónimo, C., Henrique, R., Medeiros, R., Santos, L., Silva, C., Bento, M.J., Oliveira, J., Carvalho, R. & Lopes, C. (1999). Expression of p53, bcl-2, nm-23, CD44s, CD44V6 and BL2-10 D1 and their relation to histologic grade and stage in transitional-cell carcinoma. J Urol Pathol. 10, 189-205.
(30) Santos, L., Amaro, T., Costa, C., Pereira, S., Bento, M.J., Lopes, P., Oliveira, J., Criado, B. & Lopes, C. (2003). Ki-67 index enhances the prognostic accuracy of the
urothelial superficial bladder carcinoma risk group classification. Int J Cancer. 105(2), 267-272.
(31) Santos, L.L., Amaro, T., Pereira, S.A., Lameiras, C.R., Lopes, P., Bento, M.J., Oliveira, J., Criado, B. & Lopes, C.S. (2003). Expression of cell-cycle regulatory proteins and their prognostic value in superficial low-grade urothelial cell carcinoma of the bladder. Eur J Surg Oncol. 29(1), 74-80.
(32) Miyao, N., Tsai, Y.C., Lerner, S.P., Olumi, A.F., Spruck, C.H., Gonzalez-Zulueta, M., Nichols, P.W., Skinner, D.G. & Jones PA. (1993). Role of chromosome 9 in human bladder cancer. Cancer Res. 53, 4066-4070.
(33) Orlow, I., Lianes, P., Lacombe, L., Dalbagni, G., Reuter, V.E. & Cordon-Cardo, C. (1994). Chromosome 9 allelic loss and microsatellite alterations in human bladder cancer. Cancer Res. 54, 2848-2851.
(34) Fadl-Elmula, I., Gorunova, L., Mandahl, N., Elfving, P., Lundgren, R., Mitelman, F. & Heim, S. (2000) Karyotypic characterization of urinary bladder transitional cell carcinomas. Genes Chrom Cancer. 29, 256-265.
(35) Stoehr, R., Zietz, S., Burger, M., Filbeck, T., Denzinger, S., Obermann, E.C., Hammerschmied, C., Wieland, W.F., Knuechel, R. & Hartmann, A. (2005) Deletions of chromosomes 9 and 8p in histologically normal urothelium of patients with bladder cancer. Eur Urol. 47, 58-63.
(36) Lindgren, D., Liedberg, F., Andersson, A., Chebil, G., Gudjonsson, S., Borg, A., Mansson, W., Fioretos, T. & Hoglund M. (2006). Molecular characterization of early bladder carcinomas by expression profiles, FGFR3 mutation status, and loss of 9q. Oncogene. 25(18), 2685-2696.
(37) Tsai, Y.C., Nichols, P.W., Hit, A.L., Williams, Z., Skinner, D. & Jones, P.A.
(1990). Allelic losses of chromosomes 9, 11 and 17 in human bladder cancer. Cancer Res. 50, 44-47.
(38) Sandberg, A.A., & Berger, C.S. (1994). Review of chromosome studies in urological tumors. II. Cytogenetics and molecular genetics of bladder cancer. J Urol. 151, 545- 560.
(39) Habuchi, T., Devlin, J., Elder, P.A. & Knowles, M.A. (1995). Detailed deletion mapping of chromosome 9q in bladder cancer : evidence for two tumour supressor loci. Oncogene. 11, 1671-1674.
(40) Czerniak, B., Chaturvedi, V., Li, L., Hodges, S., Johnston, D., Roy, J.Y., Luthra, R., Logothetis, C., Von Eschenbach, A.C., Grossman, H.B., Benedict, W.F. &
Batsakis, J.G. (1999). Superimposed histologic and genetic mapping of chromosome 9 in progression of human urinary bladder neoplasia: implications for a genetic model of multistep urothelial carcinogenesis and early detection of urinary bladder cancer.
Oncogene. 18, 1185-1196.
BIBLIOGRAFIA 194
(41) Presti, J.C., Reuter, V.E., Galan, T., Fair, W.R., & Cordon-Cardo, C. (1991).
Molecular genetic alterations in superficial and locally advanced human bladder cancer. Cancer Res. 51, 5405-5409.
(42) Fearon, E.R., Feinberg, A.P., Hamilton, S.H. & Vogelstein, B. (1985). Loss of genes on the short arm of chromosome 11 in bladder cancer. Nature. 318, 377-380.
(43) Shaw, M.E. & Knowles, M.A. (1995). Deletion mapping of chromosome 11 in carcinoma of the bladder. Genes Chrom Cancer. 13, 1-8.
(44) Dalbagni, G., Presti, J., Reiter, V.E., Fair, W.R. & Cordón-Cardó, C. (1993).
Genetic alterations in bladder cancer. Lancet. 342, 469-471.
(45) Cairns, P., Shaw, M.E. & Knowles, M.A. (1993). Initiation of bladder cancer may involve deletion of a tumour-supressor gene on chromosome 9. Oncogene. 8, 1083- 1085.
(46) Kowles, M.A. & Willamson, M. (1993). Mutations of H-ras is infrequent in bladder cancer: Confirmation by single-strand confirmation polymorphism and direct sequencing. Cancer Res. 53, 133-139.
(47) Czerniak, B., Deich, D., Simmons, H., Etkind, P., Herz, F. & Koss, L.G. (1990).
H-ras gene codon 12 mutation and DNA ploidy in urinary bladder carcinoma. Br J Cancer. 62, 762-763.
(48) Fontana, D., Bellina, M., Scoffone, C., Cagnazzi, E., Cappia, S., Cavallo, F. &
Russo, R. (1996). Evaluation of c-ras oncogene product (p21) in superficial bladder cancer. Eur Urol. 29, 470-476.
(49) Zhang, Z.T., Pak, J., Huang, H.Y., Shapiro, E., Sun, T.T., Pellicer, A., & Wu, X.R. (2001). Role of H-ras activation in superficial papillary pathway of urothelial tumor formation. Oncogene. 20, 1973-1980.
(50) Billerey, C., Chopin, D., Aubriot-Lorton, M.H., Ricol, D., Gil Diez de Medina, S., Van Rhijn, B., Bralet, M.P., Lefrere-Belda, M.A., Lahaye, J.B., Abbou, C.C., Bonaventure, J., Zafrani, E.S., van der Kwast, T., Thiery, J.P. & Radvanyi, F.
(2001). Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors.
Am J Pathol. 158, 1955-1999.
(51) van Rhijn, B.W., Lurkin, I., Radvanyi, F., Kirkels, W.J., van der Kwast, T.H. &
Zwarthoff, E.C. (2001). The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate. Cancer Res.
61, 1265-1268.
(52) van Rhijn, B.W., van der Kwast, T.H., Vis, A.N., Kirkels, W.J., Boeve, E.R., Jobsis, A.C. & Zwarthoff, E.C. (2004). FGFR3 and p53 characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinoma. Cancer Res. 64, 1911-1914.
(53) van Rhijn, B.W., Montironi, R., Zwarthoff, E.C., Jobsis, A.C. & van der Kwast, T.H. (2002). Frequent FGFR3 mutations in urothelial papilloma. J Pathol. 198, 245- 251.
(54) Jebar, A.H., Hurst, C.D., Tomlinson, D.C., Johnston, C., Taylor, C.F. & Knowles, M.A. (2005). FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma. Oncogene. 24, 5218-5225.
(55) Reznikoff, C.A., Belair, C.D., Yeager, T.R., Savelieva, E., Blelloch, R.H., Puthenveettil, J.A. & Cuthill, S. (1996). A molecular genetic model of human bladder cancer pathogenesis. Semin Oncol. 23, 571-584.
(56) Grossman, H.B., Liebert, M., Antelo, M., Dinney, C.P., Hu, S.X., Palmer, J.L. &
Benedict, W.F. (1998). p53 and RB expression predict progression in T1 bladder cancer. Clin Cancer Res. 4, 829-834.
(57) Jung, I. & Messing, E. (2000). Molecular Mechanisms and Pathways in Bladder Cancer Development and Progression. Cancer Control. 7(4), 325-334.
(58) Hartmann, A., Schlake, G., Zaak, D., Hungerhuber, E., Hofstetter, A., Hofstaedter, F. & Knuechel R. (2002). Occurrence of chromosome 9 and p53 alterations in multifocal dysplasia and carcinoma in situ of human urinary bladder.
Cancer Res. 62, 809-818.
(59) Shariat, S.F., Tokunaga, H., Zhou, J., Kim, J., Ayala, G.E., Benedict, W.F. &
Lerner, S.P. (2004). p53, p21, pRb and p16 expression predict clinical outcome in cystectomy with bladder cancer. J Clin Oncol. 22, 1014-1024.
(60) Hernando, E., Nahle, Z., Juan, G., Diaz-Rodriguez, E., Alaminos, M., Hemann, M., Michel, L., Mittal, V., Gerald, W., Benezra, R., Lowe, S.W. & Cordon-Cardo, C. (2004). Rb inactivation promotes genomic instability by uncoupling cell cycle progression from mitotic control. Nature. 430, 797-802.
(61) Knowles, M.A. (1998). Molecular genetics of bladder cancer: Pathways of development and progression. Cancer surveys. 31, 49-69.
(62) Cordon-Cardo, C., Zhang, Z.F., Dalbagni, G., Drobnjak, M., Charytonowicz, E., Hu, S.X., Xu, H.J., Reuter, V.E. & Benedict, W.F. (1997). Cooperative effects of p53 and pRB alterations in primary superficial bladder tumors. Cancer Res. 57, 1217- 1221.
(63) Chatterjee, S.J., Datar, R., Youssefzadeh, D., George, B., Goebell, P.J., Stein, J.P., Young, L., Shi, S.R., Gee, C., Groshen, S., Skinner, D.G. & Cote R.J. (2004).
Combined effects of p53, p21 and pRb expression in the progression of bladder transitional cell carcinoma. J Clin Oncol. 22, 1007-1013.
(64) Folkman, J. & Klagsbrun, M. (1987). Vascular physiology. A family of angiogenic peptides. Nature. 329, 671-672.
BIBLIOGRAFIA 196
(65) Bochner, B.H., Cote, R.J., Weidner, N., Groshen, S., Chen, S.C., Skinner, D.G. &
Nichols, P.W. (1995). Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis. J Natl Cancer Inst. 87, 1603-1612.
(66) Chaudhary, R., Bromley, M., Clarke, N.W., Betts, C.D., Barnard, R.J., Ryder, W.D. & Kumar, S. (1999). Prognostic relevance of micro-vessel density in cancer of the urinary bladder. Anticancer Res. 19, 3479-3484.
(67) Grossfeld, G.D., Ginsberg, D.A., Stein, J.P., Bochner, B.H., Esrig, D., Groshen, S.
& Dunn, M. (1997). Thrombospondin-1 expression in bladder cancer: association with p53 alterations, tumor angiogenesis, and tumor progression. J Natl Cancer Inst.
89, 219-227.
(68) Campbell, S.C., Volpert, O.V., Ivanovich, M. & Bouck, N.P. (1998). Molecular Mediators of Angiogenesis in Bladder Cancer. Cancer Res. 58, 1298-1304.
(69) Liebert, M., Gebhardt, D., Wood, C., Chen, I.L., Ellard, J., Amancio, D. &
Grossman, H.B. (1999). Urothelial differentiation and bladder cancer. Adv Exp Med Biol. 462, 437-448.
(70) Bringuier, P.P., Umbas, R., Schaafsma, H.E., Karthaus, F.M., Debruyne, F.M.J.
& Schalken, J.A. (1993). Decreased E-cadherin immunoreactivity correlates with poor survival in patients with bladder tumors. Cancer Res. 53, 3421-3425.
(71) Fujisawa, M., Miyazaki, J., Takechi, Y., Arakawa, S. & Kamidono, S. (1996). The significance of E-cadherin in transitional-cell carcinoma of the human urinary bladder.
World J Urol. 14, 12-15.
(72) Lipponen, P.K. & Eskelinen, M.J. (1995). Reduced expression of E-cadherin is related to invasive disease and frequent recurrence in bladder cancer. J Cancer Res Clin Oncol. 121, 303-308.
(73) Garcia del Muro, X., Torregrosa, A., Munoz, J., Castellsague, X., Condom, E., Vigues, F., Arance, A., Fabra, A. & Germa, J.R. (2000). Prognostic value of the expression of E-cadherin and β-catenin in bladder cancer. Eur J Cancer. 36, 357-362.
(74) Serdar, A., Turhan, C., Soner, G., Cem, S.N., Bayram, K., Damla, B.E. & Erbil E.
(2005). The prognostic importance of e-cadherin and p53 gene expression in transitional bladder carcinoma patients. Int Urol Nephrol. 37(3), 485-492.
(75) Lascombe I., Clairotte, A., Fauconnet, S., Bernardini, S., Wallerand, H., Kantelip, B. & Bittard, H. (2006). N-cadherin as a novel prognostic marker of progression in superficial urothelial tumors. Clin Cancer Res. 12(9), 2780-2787.
(76) Polette, M., Nawrocki-Raby, B., Gilles, C. & Clavel, C. (2004). Tumour invasion and matrix metalloproteinases. Crit Rev Oncol Hematol. 49(3), 179-186.
(77) Kanayama, H. (2001). Matrix metttalloproteinases and bladder cancer. J Med Invest.
48, 31-43.
(78) Santos, L., Amaro, T., Pereira, S., Bento, M.J., Lopes, P., Koch, A., Criado, B. &
Lopes, C.S. (2001). Alterações Moleculares do Carcinoma Papilar e Transicional da Bexiga. Uro. 6(1), 11-16.
(79) Leppert, J. T., Shvarts, O., Kawaoka, K., Lieberman, R., Belldegrun, A.S. &
Pantuck, A.J. (2006). Prevention of Bladder Cancer: A Review. Eur Urol. 49, 226- 234.
(80) Matsumoto, K., Irie, A., Satoh, T., Kuruma, H., Arakawa, T. & Baba, S. (2005).
Occupational Bladder Cancer: from cohort study to biologic molecular marker. Med Sci Monit. 11(10), 311-315.
(81) Kirkali, Z., Chan, T., Manoharan, M., Algaba, F., Busch, C., Cheng, L., Kiemeney, L., Kriegmair, M., Montironi, R., Murphy, W., Sesterhenn, I.A., Tachibana, M. & Weider, J. (2005). Bladder Cancer: Epidemiology, Staging and Grading, and Diagnosis. Urology. 66(6A), 4-34.
(82) Jankovic, S. & Radosavljevic, V. (2007). Risk factors for bladder cancer. Tumori.
93(1), 4-12.
(83) Augustine, A., Hebert, J.R., Kabat, G.C. & Wynder, E. (1998). Bladder Cancer in relation to Cigarette smoking. Cancer Res. 48, 4405-1998.
(84) Thompson, I.M., Peek, M. & Rodriguez, F.R. (1987). The impact of cigarette smoking on stage, grade and number of recurrences of transitional cell carcinoma of the bladder. J Urol. 137(3), 401-403.
(85) Wallerand, H., Bakkar, A.A., de Medina, S.G., Pairon, J.C., Yang, Y.C., Vordos, D., Bittard, H., Fauconnet, S., Kouyoumdjian, J.C., Jaurand, M.C., Zhang, Z.F., Radvanyi, F., Thiery, J.P. & Chopin, D.K. (2005). Mutations in TP53, but not FGFR3, in urothelial cell carcinoma of the bladder are influenced by smoking:
contribution of exogenous versus endogenous carcinogens. Carcinogenesis. 26(1), 177-184.
(86) Kadlubar, F.F. & Badawi, A.F. (1995). Genetic Susceptibility and Carcinogen – DNA Adduct Formation in Human Urinary Bladder Carcinogenesis. Toxicol Lett. 82, 627-632.
(87) Risch, A., Wallace, D.M., Bathers, S. & Sim, E. (1995). Slow N-acetylation Genotype is a susceptibility factor in Occupational and Smoking related Bladder Cancer. Hum Mol Gen. 4, 231-236.
(88) Yu, M.C., Skipper, P.L., Taghizadeh, K., Tannenbaum, S.R., Chan, K.K., Henderson, B.E. & Ross R.K. (1994). Acetylator phenotype, aminobiphenyl- hrmoglobin adduct levels, and bladder cancer risk in white, black, and Asian men in Los Angeles, California. J Natl Cancer Inst. 86, 712-716.
BIBLIOGRAFIA 198
(89) Vineis, P. & Simonato L. (1991). Proportion of lung and bladder cancers in males resulting from occupation: a systematic approach. Argh Environ Health. 46, 6-15.
(90) Bosetti C, Pira E & Vecchia CL. (2005). Bladder cancer risk in painters: a review of the epidemiological evidence, 1989-2004. Cancer Causes Control. 16(9), 997-1008.
(91) Kroft, H.S. & Oyasu, R. (1994). Biology of Disease - Urinary Bladder Cancer:
Mechanisms of Development and Progression. Lab Invest. 71(2), 158-174.
(92) Carreon, T., Lemasters, G.K., Ruder, A.M. & Schulte, P.A. (2006). The genetic and environmental factors involved in benzidine metabolism and bladder carcinogenesis in exposed workers. Front Biosci. 11, 2889-2902.
(93) Carreon, T., Ruder, A.M., Schulte, P.A., Hayes, R.B., Rothman, N., Waters, M., Grant, D.J., Boissy, R., Bell, D.A., Kadlubar, F.F., Hemstreet, G.P.3rd, Yin, S. &
LeMasters, G.K. (2006). NAT2 slow acetylation and bladder cancer in workers exposed to benzidine. Int J Cancer. 118(1), 161-168.
(94) Practical Science. Parasitology – Schistosoma haematobium.
Available at: http://www.practicalscience.com/schistosoma.html
(95) Lopes, C. (1984). Cancerização vesical e Schistosomíase. Tese de Doutoramento.
Faculdade de Medicina da Universidade do Porto.
(96) Badawi, A.F. (1996). Molecular and genetic in schistosomiasis-associated human bladder cancer: role and oncogenes and tumor supressor genes. Cancer Lett. 105, 123- 138.
(97) Vaidyanathan, S., Soni1, B.M., Oo, T., Hughes, P.L., Singh, G., Watt, J.W.H. &
Sett, P. (2003). Bladder stones – red herring for resurgence of spasticity in a spinal cord injury patient with implantation of Medtronic Synchromed pump for intrathecal delivery of baclofen – a case report. BMC Urology. 3, 3-9.
(98) Stonehill, W.H., Dmochowski, R.R., Patterson, A.L. & Cox, C.E. (1996). Risk factors for bladder tumors in spinal cord injury patients. J Urol. 155, 1248-1250.
(99) Travis, L.B., Curtis, R.E., Glimelius, B., Holowaty, E.J., Van Leeuwen, F.E., Lynch, C.F., Hagenbeek, A., Stovall, M., Banks, P.M., Adami, J., et al. (1995).
Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin’s lymphoma. J Natl Cancer Inst. 87, 524-530.
(100) Fernandes, E.T., Manivel, J.C., Reddy, P.K. & Ercole, C.J. (1996).
Cyclophosphamide associated bladder cancer: a highly aggressive disease. Analysis of 12 cases. J Urol. 156, 1931-1933.
(101) Cohen, S.M., Garland, E.M., St. John, M., Okamura, T. & Smith, R.A. (1992).
Acrolein initiates rat urinary bladder carcinogenesis. Cancer Res. 52, 3577-3581.
(102) Kaldor, J.M., Day, N.E., Kittelmann, B., Pettersson, F., Langmark, F., Pedersen, D., Prior, P., Neal, F., Karjalainen, S,, Bell, J., et al. (1995). Bladder tumours following chemotherapy and radiotherapy for ovarian cancer: a case-control study. Int J Cancer. 63, 1-6.
(103) Kleinerman, R.A., Boice, J.D.Jr., Storm, H.H., Sparen, P., Andersen, A., Pukkala, E., Lynch, C.F., Hankey, B.F. & Flannery, J.T. (1995). Second primary cancer after treatment for cervical cancer: an international cancer registries study.
Cancer. 76, 442-452.
(104) Neugut, A.I., Ahsan, H., Robinson, E. & Ennis, R.D. (1997). Bladder carcinoma and other second malignancies after radiotherapy for prostate carcinoma. Cancer. 79, 1600-1604.
(105) Shah, S.K., Lui, P.D., Baldwin, D.D. & Ruckle, H.C. (2006). Urothelial carcinoma after external beam radiation therapy for prostate cancer. J Urol. 175(6), 2063-2066.
(106) Quilty, P.M. & Kerr, G.R. (1987). Bladder cancer following low or high dose pelvic irradiation. Clin Radiol. 38, 583-585.
(107) Kiemeney, L.A. & Schoenberg, M. (1996). Familial transitional cell carcinoma. J Urol. 156, 867-872.
(108) Kramer, A.A., Graham, S., Burnett, W.S. & Nasca, P. (1991). Familial aggregation of bladder cancer stratified by smoking status. Epidemiology. 2, 145-148.
(109) Goldgar, D.E., Easton, D.F., Cannon-Albright, L.A. & Skolnick, M.H. (1994).
Systematic population-based assessment of cancer risk in first-degree relative of cancer probands. J Natl Cancer Inst. 86, 1600-1608.
(110) Kiemeney, L.A., Moret, N.C., Witjes, J.A., Schoenberg, M.P. & Tulinius, H.
(1997). Familial transitional cell carcinoma among the population of Iceland. J Urol.
157, 1649-1651.
(111) Jensen, O.M., Esteve, J., Moller, J. T & Renard, H. (1990). Cancer in the European Community and its Member States. Eur J Cancer. 26, 1167-1177.
(112) Ferlay, J., Bray, F., Pisani, P. & Parkin, D.M. (2004). GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide. IARC CancerBase, No. 5, version 2.0. IARC Press. Lyon. Available at: http://www-dep.iarc.fr/
(113) Silverman, D.T., Hartge, P., Morrison, A.S. & Devesa, S.S. (1992). Epidemiology of bladder cancer. Hematol Oncol Clin North Am. 6(1), 1-30.
(114) American Cancer Society. (2007). Cancer Facts & Figures 2007. American Cancer Society. Atlanta.
(115) Ferlay, J., Bray, F., Sankila, R. & Parkin, D.M. (1999). EUCAN: Cancer Incidence,
BIBLIOGRAFIA 200
Mortality and Prevalence in the European Union 1998. IARC CancerBase, No. 4, version 5.0. IARC Press. Lyon. Available at: http://www-dep.iarc.fr/eucan/eucan.htm
(116) Tyczynski, J.E. & Parkin, D. M. (2003). Bladder Cancer in Europe. ENCR Cancer Fact Sheets. 3, 1-4.
(117) World Health Statistics Annual. World Health Organization (WHO) Databank.
Geneva, Switzerland. Last updated: November 2001.
Available at: http://www.who.int/whosis/
(118) RORENO – Registo Oncológico da Região Norte, edição do Instituto Português de Oncologia Francisco Gentil – Centro do Porto 38. 1999-2000.
(119) Registo de Cancro do Instituto Português de Oncologia – Centro do Porto. 1993-2002.
(120) Ro, J.Y., Staerkel, G.A. & Ayala, A.G. (1992). Citologic and Histologic features of superficial bladder cancer. Urol Clin North Am. 19(3), 435-453.
(121) Lee, R. & Droller, M.J. (2000). The natural history of bladder cancer. Implications for therapy. Urol Clin North Am. 27, 1-13.
(122) Greene, F.L., Page, D.L., Fleming, I.D., Fritz, A.G., Balch, C.M., Haller, D.G. &
Morrow, M. (2002). AJCC Cancer Staging Manual. Sixth edition. Springer Verlag.
New York.
(123) Sobin, L.H. & Wittekind, C. (1997). TNM Classification of malignant tumors. Fifth edition. John Wiley & Sons, Inc. New York.
(124) van der Meijden, A.P.M. (1998). Bladder Cancer. BMJ. 317,1366-1369.
(125) Heney, N.M. (1992). Natural history of superficial bladder cancer. Urol Clin North Am. 19(3), 429-433.
(126) Montironi, R. & Mazzucchelli, R. (2003). Preneoplastic Lesions and Conditions of the Urinary Bladder. EUA Update Series. 1, 53-63.
(127) Montironi, R., Lopez-Beltran, A., Mazzucchelli, R. & Bostwick, D.G. (2003).
Classification and grading of the non-invasive urothelial neoplasms: recent advances and controversies. J Clin Pathol. 56, 91-95.
(128) Mostofi, F.K., Sorbin, L.H. & Torloni, H. (1973). Histological typing of urinary bladder tumours. International Classification of Tumours, 19. World Health Organization. Geneva.
(129) Epstein, J.I., Amin, M.B., Reuter, V. & Mostofi, F.K. (1998). The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol. 22(12), 1435-1448.
(130) Mostofi, F.K., Davis, C.J. & Sesterhenn, I.A. (1999). Histological typing of urinary bladder tumours. World Health Organization, International Histological Classification of Tumours. Second Edition. Springer-Verlag. Berlin.
(131) Ebler, J.N., Sauter, G., Epstein, J.I. & Sesterhenn, I.A., for the International Agency for Research on Cancer (2004). Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. IARC Press. Lyon.
(132) Lopez-Beltran, A. & Montironi, R. (2004). Non-Invasive Urothelial Neoplasms : According to the Most Recent WHO Classification. Eur Urol. 46, 170-176.
(133) Holmang, S. & Johansson, S.L. (2005). Urothelial Carcinoma of the Upper Urinary Tract: comparison between the WHO/ISUP 1998 consensus classification and WHO 1999 classification system. Urology. 66(2), 274-278.
(134) Busch, C. & Algaba, F. (2002). The WHO/ISUP 1998 and WHO 1999 Systems for malignancy grading of bladder cancer. Scientific foundation and translation to one another and previous systems. Virchows Arch. 441, 105-108.
(135) Bostwick, D.G. & Mikuz, G. (2002). Urothelial papilary (exophytic) neoplasms.
Virchows Arch. 441, 109-116.
(136) McKenney, J.K., Amin, M.B. & Young, R.H. (2003). Urothelial (transitional cell) papilloma of the urinary bladder: a clinicopathologic study of 26 cases. Mod Pathol.
16, 623-629.
(137) Cheng, L., Darson, M., Cheville, J.C., Neumann, R.M., Zincke, H., Nehra, A. &
Bostwick, D.G. (1999). Urothelial papilloma of the bladder. Clinical and biologic aplication. Cancer. 86(10), 2098-2101.
(138) Calais da Silva, F. (editor). (2002). Carcinoma da Bexiga – Perspectiva Actual. 1º edição. Seleprinter, Artes Gráficas. Lisboa (Patrocínio da Fundação Schering Lusitana).
(139) Jones, T.D. & Cheng, L. (2006). Papillary urothelial neoplasm of low malignant potential: evolving terminology and concepts. J Urol. 175(6), 1995-2003.
(140) Cheng L., Neumann, R.M. & Bostwick, D.G. (1999). Papillary urothelial neoplasms of low malignant potentional. Clinical and biologic implications. Cancer. 86, 2102- 2108.
(141) Oosterhuis, J.W.A., Schapers, R.F.M., Janssen-Heijnen, M.L.G., Pauwels, R.P.E., Newling, D.W. & ten Kate, F. (2002). Histological grading of papillary urothelial carcinoma of tha bladder: prognostic value of the 1998 WHO/ISUP classification system and comparison with conventional grading systems. J Clin Pathol. 55, 900- 905.
(142) Desai, S., Lim, S.D., Jimenez, R.E., Chun, T., Keane, T.E., McKenney, J.K.,
BIBLIOGRAFIA 202
Zavala-Pompa, A., Cohen, C., Young, R.H. & Amin MB. (2000). Relationship of cytokeratin 20 and CD44 protein expression with WHO/ISUP grade in pTa and pT1 papillary urothelial neoplasia. Mod Pathol. 13, 1315-1323.
(143) Sauter, G., Algaba, F., Amin, M., Busch, C., Cheville, J., Gasser, T., Grignon, D.J., Hofstadter, F., Lopez-Beltran, A. & Epstein, J.I. (2004). Non-Invasive Urothelial Neoplasias. WHO Classification of Non Invasive Papillary Urothelial Tumors. In Eble, J.N., Sauter, G., Epstein, J.I. & Sesterhenn, I.A., World Health Organization Classification of Tumours. Pathology and Genetics: Tumors of the Urinary System and Male Genital Organs. IARCC Press. Lyon.
(144) Hudson, M.A. & Herr, H.W. (1995). Carcinoma in situ of the bladder. J Urol. 153, 564-572.
(145) McKeney, J.K., Gomez, J.A., Desai, S., Lee, M.W. & Amin, M.B. (2001).
Morphologic expressions of urothelial carcinoma in situ: a detailed evaluation of its histologic patterns with emphasis on carcinoma in situ with microinvasion. Am J Surg Pathol. 31, 745-750.
(146) Duque, J.L. & Loughlin, K.R. (2000). An overview of the treatment of superficial bladder cancer. Intravesical chemotherapy. Urol Clin North Am. 27, 125-135.
(147) Sakai, I., Miyake, H., Harada, K., Hara, I., Inoue, T.A. & Fujisawa, M. (2006).
Analysis of factors predicting intravesical recurrence of superficial transitional cell carcinoma of the bladder without concomitant carcinoma in situ. Int J Urol. 13, 1389- 1392.
(148) Dutta, S.C., Smith, J.A. Jr., Shappell, S.B., Coffey, C.S., Changt, S.S. & Cookson, M.S. (2001). Clinical understaging of high risk nonmuscle invasive urothelial carcinoma treated with radical cyctectomy. J Urol. 166, 490-493.
(149) Herr, H.W. (2000). Tumor progression and survival of patients with high grade, noninvase papillary (TaG3) bladder tumours: 15-year outcome. J Urol. 163, 60-62.
(150) Wiesner, C., Pfitzenmaier, J., Faldum, A., Gillitzer, R., Melchior, S.W. &
Thüroff, J.W. (2005). Lymph node metastases in non-muscle invasive bladder cancer are correlated with the number of transurethral ressections and tumour upstaging at radical cystectomy. BJU International. 95, 301-305.
(151) Sleeman, J.P. (2000). The lymph node as a bridgehead in the metastatic dissemination of tumours. Recent Results Cancer Res. 1654, 3-12.
(152) Stacker, S.A., Achen, M.G., Jussila, L., Baldwin, M.E. & Alitalo, K. (2002).
Metastasis: lymphangiogenesis and cancer metastasis. Nat Rev Cancer. 2, 573-583.
(153) Abdel-Latif, M. (2005). Which clinical variables are associated with lymph node metastases in patients with superficial bladder cancer? Nat Clin Pract Urol. 2(5), 214- 215.
(154) Solsona, E., Iborra, I., Rubio, J., Casanova, J. & Almenar, S. (2004). The optimum timing of radical cystectomy for patients with recurrent high-risk superficial bladder tumour. BJU Int. 94, 1258-1262.
(155) May, M., Helke, C., Nitzke, T., Vogler, H. & Hoschke, B. (2004) Survival rates after radical cystectomy according to tumor stage of bladder carcinoma at first presentation. Urol Int. 72(2), 103-111.
(156) Skinner, D.G., Stein, J.P., Lieskovsky, G., Skinner E.C., Boyd S.D., Figueroa A., Jones P., Cote R. & Groshen S. (1998). 25-year experience in the management of invasive bladder cancer by radical cistectomy. Eur Urol. 33(4), 25-26.
(157) Quek, M.L., Stein, J.P., Daneshmand, S., Miranda, G., Thangathurai, D., Roffey, P., Skinner, E.C., Lieskovsky, G. & Skinner, D.G. (2006). A critical analysis ot perioperative mortality from radical cystectomy. J Urol. 175(3), 886-889.
(158) Boccardo, F. & Palmeri, L. (2006). Adjuvant chemotherapy of bladder cancer. Ann Oncol. 17(5), 129-132.
(159) Passaperuma, K., Ash, R., Venkatesan, V., Rodrigues, G. & Winguis, E. (2006).
Pelvic chemoradiotherapy after chemotherapy for metastatic bladder cancer. Can J Urol. 13(2), 3009-3015.
(160) Cohen, S.M., Goel, A., Phillips, J., Ennis, R.D. & Grossbard, M.L. (2006). The Role of Perioperative Chemotherapy in the Treatment of Urothelial Cancer.
Oncologist. 11, 630-640.
(161) Stein, J.P., Lieskovsky, G., Cote, R., Groshen, S., Feng, A.C., Boyd, S., Skinner, E., Bochner, B., Thangathurai, D., Mikhail, M., Raghavan, D. & Skinner, D.G.
(2001). Radical Cystectomy in the treatment of invasive bladder cancer: long term results in 1054 patients. J Clin Oncol. 19, 666-675.
(162) May, M., Nitzke, T., Helke, C., Vogler, H. & Hoschke, B. (2004). Significance of the time period between diagnosis of muscle invasion and radical cystectomy with regard to the prognosis of transitional cell carcinoma of the urothelium in the bladder.
Scand J Urol Nephrol. 38(3), 231-235.
(163) Fradet, Y., Aprikian, A., Dranitsaris, G., Siemens, R., Tsihlias, J., Fleshner, N. &
Canadian surgical wait times (SWAT) initiative. (2006). Does prolonging the time to bladder cancer surgery affect long-term cancer control: a systematic review of the literature. Can J Urol. 13(3), 37-47.
(164) Stein, J.P. & Skinner, D.G. (2005). The role of lymphadenectomy in high-grade invasive bladder cancer. Urol Clin North Am. 32(2), 187-197.
(165) Vieweg, J., Gschwend, J.E., Herr, H.W. & Fair, W.R. (1999). Pelvic lymph node dissection can be curative in patientts with node positive bladder cancer. J Urol. 161, 449-454.
BIBLIOGRAFIA 204
(166) Leissner, J. Hohenfellner, R., Thuroff, J.W. & Wolf, H.K. (2000).
Lymphadenectomy in patients with transitional cell carcinoma of the urinary bladder, significance for staging and prognosis. BJU Int. 85, 817-823.
(167) Ather, M.H., Fatima, S. & Sinanoglu, O. (2005). Extent of lymphadenectomy in radical cystectomy for bladder cancer. World J Clin Oncol. 3, 43-47.
(168) Nagele, U., Anastasiadis, A.G., Merseburger, A.S., Sievert, K.D., Stenzl, A. &
Kuczyk, M. (2006). Clinical outcomes after cystectomy in patients with lymph node- positive bladder cancer. Expert Rev Anticancer Ther. 6(6), 871-876.
(169) Dhar, N.B., Campbell, S.C., Zippe, C.D., Derweesh, I.H., Reuther, A.M., Fergany, A. & Klein, E.A. (2006). Outcomes in patients with urothelial carcinoma of the bladder with limited pelvic lymph node dissection. BJU Int. 98(6), 1172-1175.
(170) Abol-Enein, H., El-Baz, M., Abd El-Hameed, M.A., Abdel-Latif, M. & Ghoneim, M.A. (2004). Lymph node involvement in patients with bladder cancer treated with radical cystectomy: a patho-anatomical study – a single center experience. J Urol.
172(5 Pt 1), 1818-1821.
(171) Poulsen, A.L., Horn, T. & Steven, K. (1998). Radical cystectomy: extending the limits of pelvic node dissection improved survival for patients with bladder cancer confined to the bladder wall. J Urol. 160, 2015-2019.
(172) Stein, J.P., Cai, J., Groshen, S. & Skinner, D.G. (2003). Risk factors for patients with pelvic lymph node metastases following radical cystectomy with en bloc pelvic lymphadenectomy: the concept of lymph node density. J Urol. 170, 35-41.
(173) Ghoneim, M.A. & Abol Enein., H. (2004). Lymphadenectomy with cystectomy: Is it necessary and what is its extent. Eur Urol. 45, 457-461.
(174) Herr, H.W., Faulkner, J.R., Grossman, H.B., Natale, R.B., White, R., Sarosdy, M.
& Crawford, E.D. (2004). Surgical Factores influence Bladder Cancer Outcomes: A Cooperative Group Report. J Clin Oncol. 22(14), 2781-2789.
(175) Stein, J.P. (2006). Lymphadenectomy in bladder cancer : How high is “high enough”?
Urol Oncol. 24, 349-355.
(176) Sanderson, K.M., Skinner, D. & Stein, J.P. (2006). The prognostic and staging value of lymph node dissection in the treatment of invasive bladder cancer. Nat Clin Pract Urol. 3(9), 485-494.
(177) Honma, I., Masumori, N., Sato, E., Maeda, T., Hirobe, M., Kitamura, H., Takahashi, A., Itoh, N., Tamakawa, M. & Tsukamoto T. (2006). Removal of more lymph nodes may provide better outcome, as well as more accurate pathologic findings, in patients with bladder cancer – analysis of role of pelvic lymph node dissection. Urology. 68(3), 543-548.
(178) Kassouf, W., Leibovici, D., Munsell, M.F., Dinney, C.P., Grossman, H.B. &
Kamat, A.M. (2006). Evaluation of the relevance of lymph node density in a contemporary series of patients undergoing radical cystectomy. J Urol. 176(1), 53-57.
(179) Algaba, F. (2006). Lymphovascular invasion as a prognostic tool for advanced bladder cancer. Curr Opin Urol. 16(5), 367-371.
(180) Siewert, J.R., Bottcher, K., Stein, H.J., Roder, J.D. & the German Gastric Carcinoma Study Group. (1998). Relevant prognostic factors in gastric cancer. Ann Surg. 228, 449-461.
(181) Caplin, S., Cerottini, J.P., Bosman, F.T., Constanda, M.T. & Givel, J.C. (1998).
For patients with Duke’s B (TNM Stage II) colorectal carcinoma, examination of six or fewer lymph nodes is related to poor prognosis. Cancer. 83, 666-672.
(182) Mathiesen, O., Carl, J., Bonderup, O. & Panduro, J. (1990). Axillary sampling and the risk of erroneous staging of breast cancer. Acta Oncol. 29, 721-725.
(183) Burkhard, F.C., Scumacher, M. & Studer, U.E. (2005). The role of lymphadenectomy in prostate cancer. Nat Clin Pract Urol. 2(7), 336-342.
(184) Denis, F., Garaud, P., Manceau, A., Beuter, P., Garand, G., le Floch, O. & Calais, G. (2001). Prognostic value of the number of involved nodes after neck dissection in oropharyngeal and oral cavity carcinoma. Cancer Radiother. 5(1), 12-22.
(185) Werner, J.A. & Davis, R.K. (2005). Metastases in Head and Neck Cancer. Springer.
London.
(186) Jeltsch, M. (2002). VEGFR-3 Ligands and Lymphangiogenesis. Academic dissertation. Faculty of Science of the University of Helsinki.
(187) Sadler, T.W. (2001). Langman Embriologia Médica. Oitava edição. Guanabara Koogan. Rio de Janeiro.
(188) Saharinen, P., Tammela, T., Karkkainen, M. & Alitalo, K. (2004). Lymphatic vasculature: development, molecular regulation and role in tumor metastasis and inflammation. TRENDS in Immunol. 25(7), 387-395.
(189) Swartz, M.A. (2001). The physiology of the lymphatic system. Adv Drug Del Rev. 50, 3-20.
(190) Oliver, G. & Detmar, M. (2002). The rediscovery of the lymphatic system: old and new insights into the development and biological function of the lymphatic vasculature. Genes & Develop. 16, 773-783.
(191) Williams, P.L., Warwick, R., Dyson, M. & Bannister, L.H. (1995). Gray Anatomia.
37ª edição. Guanabara Koogan. Rio de Janeiro.
BIBLIOGRAFIA 206
(192) Trzewik, J., Mallipattu, S.K., Artmann, G.M., Delano, F.A. & Schmid-Schonbein, G.W. (2001). Evidence for a second valve system in lymphatics: endothelial microvalves. FASEB J. 15(10), 1711-1717.
(193) Schmid-Schonbein, G.W. (2003). The second valve system in lymphatics. Lymphatic Res Biol. 1(1), 25-29.
(194) Solito, R., Alessandrini, C., Fruschelli, M., Pucci, A.M. & Gerli, R. (1997). An immunological correlation between the anchoring filaments of initial lymph vessels and the neighboring elastic fibers: a unified morphofunctional concept. Lymphology.
30(4), 194-202.
(195) Rodrigues, C. (2003). Anatomia Aplicada do Sistema Linfático. In Pitta, G.B.B, Castro, A.A., Burihan, E., Angiologia e Cirurgia Vascular: Guia Ilustrado.
UNCISAL/ECMAL & LAVA. Maceió. Disponível em: http://www.lava.med.br/livro.
(196) Gashev, A.A. (2002). Physiologic aspects of lymphatic contractile function: current perspectives. Ann N Y Acad Sci. 979, 178-187.
(197) Bridenbaugh, E.A., Gashev, A.A. & Zawieja, D.C. (2003). Lymphatic muscle: a review of contractile function. Lymphatic Res Biol. 1(2), 147-158.
(198) Widmaier, E.P., Raff, H. & Strang, K. (2006). Vander’s Human Phisiology – The Mechanisms of Body Function. Tenth edition. McGraw-Hill. New York.
(199) Blum, K. & Pabst, R. (2006). Keystones in lymph node development. J Anat. 209, 585-595.
(200) Szuba, A., Shin, W.S., Strauss, W. & Rockson, S. (2003). The Third Circulation:
Radionucleotide Lymphoscintigraphy in the Evaluation of Lymphedema. J Nucl Med.
44, 43-57.
(201) Poggi, P., Marchetti, C., Tazzi, A. & Scelsi, R. (1995). The lymphatic vessels and their relationship to lymph formation in the human urinary bladder. Lymphology.
28(1), 35-40.
(202) Rockson, S.G. (2001) Lymphedema. Am J Med. 110, 288–295.
(203) Alitalo, K., Tammela, T. & Petrova, T. (2005). Lymphangiogenesis in development and human disease. Nature. 438, 946-953.
(204) Pepper, M.S. (2001). Lymphangiogenesis and Tumor Metastasis: Myth or Reality.
Clin Can Res. 7, 462-468.
(205) Smith, J.A. & Whitmore, W.F.Jr. (1981). Regional lymph node metastasis from bladder cancer. J Urol. 126, 591-593.
(206) Leissner, J., Ghoneim, M.A., Abol-Enein, H., Thuroff, J.W., Franzaring, L.,
Fisch, M., Schulze, H., Managadze, G., Allhoff, E.P., el-Baz, M.A., Kastendieck, H., Buhtz, P., Kropf, S., Hohenfellner, R. & Wolf, H.K. (2004). Extended radical lymphadenectomy in patients with urothelial bladder cancer: Results of a prospective multicenter study. J Urol. 171, 139-144.
(207) Vazina, A., Dugi, D., Shariat, S.F., Evans, J., Link, R. & Lerner, S.P. (2004).
Stage specific lymph node metastasis mapping mapping in radical cystectomy specimens. J Urol. 171, 1830-1834.
(208) Bochner, B.H., Cho, D., Herr, H.W., Donat, M., Kattan, M.W. & Dalbgani, G.
(2004). Prospective packaged lymph node dissections with radical cystectomy:
Evaluation of node count variability and node mapping. J Urol. 172, 1286-1290.
(209) Mills, R.D., Turner, W.H., Fleischmann, R., Markwalder, R., Thalmann, G.N. &
Studer, U.E. (2001). Pelvic lymph node metastasis from bladder cancer: Outcome in 83 patients after radical cystectomy and pelvic lymphadenectomy. J Urol. 166, 19-23.
(210) Herr, H.W. (2003). Surgical factors in bladder cancer: More (nodes) + more (pathology) = less (mortality). BJU Int. 92,187-188.
(211) Herr, H., Lee, C., Chang, S., Lerner, S., Bladder Cancer Collaborative Group, et al. (2004). Standardization of radical cystectomy and pelvic lymph node dissection for bladder cancer; a collaborative group report. J Urol. 171, 1823-1828.
(212) Alitalo, K. & Carmeliet, P. (2002). Molecular mechanisms of lymphangiogenesis in health and disease. Cancer Cell. 1, 219-227.
(213) Karpanen, T. & Mäkinen, T. (2006). Regulation of lymphangiogenesis – From cell fate determination to vessel remodeling. Exp Cell Res. 312, 575-583.
(214) Noh, K.W., Bouras, E.P., Bridges, M.D., Nakhleh, R.E. & Nguyen, J.H. (2005).
Gallbladder lymphangioma: a case report and review of the literature. J Hepatobiliary Pancreat Surg. 12, 405-408.
(215) Janse, A.J, van Coevorden, F., Peterse, H., Keus, R.B. & van Dongen, J.A. (1995).
Lymphedema-induced lymphangiosarcoma. Eur J Surg Oncol. 21(2), 155-158.
(216) Jussila, L., Valtola, R., Partanen, T.A., Salven, P., Heikkila, P., Matikainen, M.T., Renkonen, R., Kaipainen, A., Detmar, M., Tschachler, E., Alitalo, R. & Alitalo, K. (1998). Lymphatic endothelium and Kaposi’s sarcoma spindle cells detected by antibodies against the vascular endothelial growth factor receptor-3. Cancer Res. 58, 1599-1604.
(217) Weninger, W., Partanen, T.A., Breiteneder-Geleff, S., Mayer, C., Kowalski, H., Mildner, M., Pammer, J., Sturzl, M., Kerjaschki, D., Alitalo, K. & Tschachler, E.
(1999). Expression of vascular endothelial growth factor receptor-3 and podoplanin suggests a lymphatic endothelial cell origin of Kaposi’s sarcoma tumor cells. Lab Invest. 79, 243-251.
BIBLIOGRAFIA 208
(218) Beasley, N.J.P., Prevo, R., Banerji, S., Leek, R.D., Moore, J., van Trappen, P., Cox, G., Harris, A.L. & Jackson, D.G. (2002). Intratumoral lymphangiogenesis and lymph node metastasis in head and neck cancer. Cancer Res. 62, 1315-1320.
(219) Hall, F.T., Freeman, J.L., Asa, S.L. Jackson, D.G. & Beasley, N.J. (2003).
Intratumoral lymphatics and lymph node metastases in papillary thyroid carcinoma.
Arch Otolaryngol Head Neck Surg. 129, 716-719.
(220) Straume, O., Jackson, D.G. & Akslen, L.A. (2003). Independent prognostic impact of lymphatic vessel density and presence of low-grade lymphangiogenesis in cutaneous melanoma. Clin Cancer Res. 9, 250-256.
(221) McCarter, M.D., Clarke, J.H. & Harken, A.H. (2004). Lymphangiogenesis is pivotal to the trials of a successful cancer metastasis. Surgery. 135(2), 121-124.
(222) Stacker, S.A., Baldwin, M.E. & Achen, M.G. (2002). The role of tumor lymphangiogenesis in metastatic spread. FASEB J. 16, 922-934.
(223) Hirakawa, S. & Detmar, M. (2004). New insights into the biology and pathology of the cutaneous lymphatic system. J Dermatol Sci. 35, 1-8.
(224) Scavelli, C., Weber, E., Aglianò, M., Cirulli, T., Nico, B., Vacca, A. & Ribatti, D.
(2004). Lymphatics at the crossroads of angiogenesis and lymphangiogenesis. J Anat.
204, 433-449.
(225) Oliver, G. (2005). Lymphatic vasculature development. Nature Rev Immunol. 4, 35- 45.
(226) Tammela, T., Petrova, T.V. & Alitalo, K. (2005). Molecular lymphangiogenesis:
new players. Trends Cell Biol. 15, 434-441.
(227) Risau, W. (1997). Mechanisms of angiogenesis. Nature. 386 (6626), 671-674.
(228) Risau, W. (1998). Development and differentiation of endothelium. Kidney Int Suppl.
67, S3-6.
(229) Jussila, L. & Alitalo, K. (2002). Vascular Growth Factors and Lymphangiogenesis.
Physiol Rev. 82, 673-700.
(230) Folkman, J. (1971). Tumor angiogenesis: therapeutic implications. N Engl J Med.
285, 1182-1186.
(231) Folkman, J. (1972). Anti-angiogenesis: new concept for therapy of solid tumors. Ann Surg. 175, 409-416.
(232) Kerbel, R.S. (2000). Tumor angiogenesis: past, present and the near future.
Carcinogenesis. 21(3), 505-515.
(233) National Cancer Institute, available at:
http://newscenter.cancer.gov/images/understandingcancer/PDFs/ANGIOGEN.PDF
(234) Kaipainen, A., Korhonen, J., Mustonen, T., van Hinsbergh, V.W., Fang, G.H., Dumont, D., Breitman, M. & Alitalo, K. (1995). Expression of the fms-like tyrosine kinase FLT4 gene becomes restricted to lymphatic endothelium during development.
Proc Natl Acad Sci. 92, 3566-3570.
(235) Wigle, J.T. & Oliver, G. (1999). Prox1 function is required for the development of the murine lymphatic system. Cell. 98, 769-778.
(236) Wigle, J.T., Harvey, N., Detmar, M., Lagutina, I., Grosveld, G., Gunn, M.D., Jackson, D.G. & Oliver, G. (2002). An essential role for Prox1 in the induction of the lymphatic endothelial cell phenotype. EMBO J. 21(7), 1505-1513.
(237) Hong, Y., Harvey, Y.K., Noh, Y.H., Schacht, V., Hirakawa, S., Detmar, M. &
Oliver, G. (2002). Prox1 is a master control gene in the program specifying lymphatic endothelial cell fate. Dev Dyn. 225 (3), 351-357.
(238) Petrova, T.V., Makinen, T., Makela, T.P., Saarela, I., Vertanen I., Ferrell, R.E., Finegold, D.N., Kerjaschki, D., Yla-Hertuala, S. & Alitalo, K. (2002). Lymphatic endothelial reprogramming of vascular endothelial cells by the Prox-1 homeobox transcription factor. EMBO J. 21, 4593-4599.
(239) Oliver, G.T. & Harvey, N. (2002). A steptwise model of the development of lymphatic vasculature. Ann N Y Acad Sci. 979, 159-165.
(240) Karkkainen, M.J., Haiko, P., Sainio, K., Partanen, J., Taipale, J., Petrova, T.V., Jeltsch, M,, Jackson, D.G., Talikka, M., Rauvala, H., Betsholtz, C. & Alitalo, K.
(2004). Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins. Nat Immunol. 5, 74-80.
(241) Paavonen, K., Puolakkainen, P., Jussila, L., Jahkola, T. & Alitalo, K. (2000).
Vascular endothelial growth factor receptor-3 in lymphangiogenesis in wound healing.
Am J Pathol. 156(5), 1499-1504.
(242) Jain, R.K. & Fenton, B.T. (2002). Intratumoral lymphatic vessels: a case of mistaken identity or malfunction? J Natl Cancer Inst. 94, 417-421.
(243) Zinovieva, R. D., Duncan, M. K., Johnson, T. R., Torres, R., Polymeropoulos, M.
H. & Tomarev, S. I. (1996). Structure and chromosomal localization of the human homeobox gene Prox 1. Genomics. 35, 517-522.
(244) Ferrara, N. & Davis-Smyth, T. (1997). The Biology of Vascular Endothelial Growth Factor. End Rev. 18(1), 4-25.
(245) McDonald, N.Q. & Hendrickson, W.A. (1993). A structural superfamily of growth factors containing a cystine knot motif. Cell. 73(3), 421-424.
BIBLIOGRAFIA 210
(246) Shibuya, M. (2001). Structure and Function of VEGF/VEGF-receptor System Involved in Angiogenesis. Cell Struct Func. 26, 25-35.
(247) Byrne, A.M., Bouchier-Hayes, D.J. & Harmey, J.H. (2005). Angiogenic and cell survival functions of Vascular Endothelial Growth Factor (VEGF). J Cell Mol Med.
9(4), 777-794.
(248) Karkkainen, M.J. & Petrova, T.V. (2000). Vascular endothelial growth factor receptors in the regulation of angiogenesis and lymphangiogenesis. Oncogene. 19, 5598-5605.
(249) Leung, D.W., Cachianes, G., Kuang, W-J., Goeddel, D.V. & Ferrara, N. (1989).
Vascular endothelial growth factor is a secreted angiogenic mitogen. Science. 246, 1306-1309.
(250) Carmeliet, P., Ferreira, V., Breier, G., Pollefeyt, S., Kieckens, L., Gertsenstein, M., Fahrig, M., Vandenhoeck, A., Harpal, K., Ebenhardt, C., Declercq, C., Pawling, J., Moons, L., Collen, D., Risau, W. & Nagy, A. (1996). Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature.
380, 435-439.
(251) Ferrara, N., Carver-Moore, K., Chen, H., Dowd M., Lu, L., O’Shea, K.S., Powell- Braxton, L., Hillan, K.J. & Moore, M.W. (1996). Heterozygous embrionic lethality induced by targeted inactivation of the VEGF gene. Nature. 380, 439-442.
(252) Dvorak, H.F., Harvey, V.S., Estrella, P., Brown, L.F., McDonagh, J. & Dvorak, A.M. (1987). Fibrin containing gels induce angiogenesis: implications for tumor stroma generation and wound healing. Lab Invest. 57, 673-686.
(253) Dvorak, H.F., Brown, L.F., Detmar, M. & Dvorak, A.M. (1995). Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol. 146, 1029-1039.
(254) Ferrara, N. (2000). VEGF: an updated on biological and therapeutic aspects. Curr Opin Biotechnol. 11, 617-624.
(255) Tischer, E., Mitchell, R., Hartman, T., Silva, M., Gospodarowicz, D., Fiddes, J.C.
& Abraham, J.A. (1991). The human gene for vascular endothelial growth factor.
Multiple protein forms are encoded through alternative exon splicing. J Biol Chem.
266, 11947-11954.
(256) Olofsson, B., Pajusola, K., Kaipainen, A., von Euler, G., Joukov, V., Saksela, O., Orpana, A., Pettersson, R.F., Alitalo, K. & Eriksson, U. (1996). Vascular endothelial growth factor B, a novel growth factor for endothelial cells. Proc Natl Acad Sci USA. 93, 2576-2581.
(257) Carmeliet, P., Moons, L., Luttun, A., Vincenti, V., Compernolle, V., De Mol, M., Wu, Y., Bono, F., Devy, L., Beck, H., Scholz, D., Acker, T., DiPalma, T.,
Dewerchin, M., Noel, A., Stalmans, I., Barra, A., Blacher, S., Vandendriessche, T., Ponten, A., Eriksson, U., Plate, K.H., Foidart, J.M., Schaper, W., Charnock- Jones, D.S., Hicklin, D.J., Herbert, J.M., Collen, D. & Persico, M.G. (2001).
Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions.
Nat Med. 7 (5), 575-83.
(258) Luttun, A., Tjwa, M., Moons, L., Wu, Y., Angelillo-Scherrer, A., Liao, F., Nagy, J.A., Hooper, A., Priller, J., De Klerck, B., Compernolle, V., Daci, E., Bohlen, P., Dewerchin, M., Herbert, J.M., Fava, R., Matthys, P., Carmeliet, G., Collen, D., Dvorak. H.F., Hicklin, D.J. & Carmeliet, P. (2002). Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med. 8 (8), 831-40.
(259) Joukov, V., Sorsa, T., Kumar, V., Jeltsch, M., Claesson-Welsh, L., Cao, Y., Saksela, O., Kalkkinen, N. & Alitalo, K. (1997). Proteolytic processing regulates receptor specificity and activity of VEGF-C. EMBO J. 16, 3898-3911.
(260) Stacker, S.A., Stenvers, K., Caesar, C., Vitali, A., Domagala, T., Nice, E., Roufail, S., Simpson, R.J., Moritz, R., Karpanen, T., Alitalo, K & Achen, M.G. (1999).
Biosynthesis of vascular endothelial growth factor-D involves proteolytic processing wich generates non-covalent homodimers. J Biol Chem. 274, 32127-32136.
(261) Kukk, E., Lymboussaki, A., Taira, S., Kaipanen, A., Jeltsch, M., Joukov, V. &
Alitalo, K. (1996). VEGF-C receptor binding and pattern of expression with VEGFR- 3 suggests a role in lymphatic vascular development. Development. 122, 3829-3837.
(262) Baldwin, M.E., Halford, M.M., Roufail, S., Williams, R.A., Hibbs, M.L. Grail, D., Kubo, H., Stacker, S.A. & Achen, M.G. (2005). Vascular Endothelial Growth Factor D is dispensable for Development of the Lymphatic System. Mol Cell Biol. 25(6), 2441-2449.
(263) Achen, M.G., Jeltsch, M., Kukk, E., Makinen, T., Vitali, A., Wilks, A.F., Alitalo, K. & Stacker, S.A. (1998). Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4).
Proc Natl Acad Sci. 95, 548-553.
(264) Joukov, V., Pajusola, K., Kaipainen, A., Chilov, D., Lahtinen, I., Kukk, E.
Saksela, O., Kalkkinen, N. & Alitalo, K. (1996). A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J. 15, 290-298.
(265) Makinen, T., Veikkola, T., Mustjoki, S., Karpanen, T., Catimel, B., Nice, E.C., Wise, L., Mercer, A., Kowalski, H., Kerjaschki, D., Stacker, S.A., Achen, M.G. &
Alitalo, K. (2001b). Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF-C/D receptor VEGFR-3. EMBO J. 20, 4762- 4773.
BIBLIOGRAFIA 212
(266) Fournier, E., Birnbaum, D. & Borg, J.P. (1997). Receptors for factores of the VEGF family. Bull Cancer. 84, 397-403.
(267) Shibuya, M. & Claesson-Welsh, L. (2006). Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Exp Cell Res. 312, 549-560.
(268) Neufeld, G., Cohen, T, Gengrinovirch, S. & Poltorak, Z. (1999). Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 13, 9-22.
(269) Al-Rawi, M.A.A., Mansel, R.E. & Jiang, W.G. (2005). Molecular and cellular mechanisms of lymphangiogenesis. EJSO. 31, 117-121.
(270) Dumont, D.J., Jussila, L., Taipale, J., Lymboussaki, A., Mustonen, T., Pajusola, K., Breitman, M. & Alitalo, K. (1998). Cardiovascular failure in mouse embryos deficient in VEGF receptor-3. Science. 282, 946-949.
(271) Stacker, S.A., Hughes, R.A. & Achen, M.G. (2004). Molecular targeting of lymphatics for therapy. Curr Pharm Des. 10, 65-74.
(272) Makinen, T., Jussila, L., Veikkola, T., Karpanen, T., Ketunen, M.I., Pulkkanen, K.J., Kauppinen, R., Jackson, D.G., Hubo, H., Nishikawa, S., Yla-Herttuala, S. &
Alitalo, K. (2001). Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3. Nat Med. 7, 199-205.
(273) Pytowski, B., Goldman, J., Persaud, K., Wu, L., Witte, L., Hicklin, D.J., Skobe, M., Boardman, K.C. & Swartz, M.A. (2005). Complete and specific inhibition of adult lymphatic regeneration by a novel VEGFR-3 neutralizing antibody. J Natl Cancer Inst. 97, 14-21.
(274) Karkkainen, M.J., Ferrell, R.E., Lawrence, E.C., Kimak, M.A., Levinson, K.L., McTigue, M.A., Alitalo, K. & Finegold, D.N. (2000). Missense mutations interfere with VEGFR-3 signalling in primary lymphoedema. Nat Genet. 25, 153-159.
(275) Partanen, T.A., Arola, J., Saaristo, A., Jussila, L., Ora, A., Miettinen, M., Stacker, S.A., Achen, M.G. & Alitalo, K. (2000). VEGF-C and VEGF-D expression in neuroendocrine cells and their receptor, VEGFR-3, in fenestrated blood vessels in human tissues. FASEB J. 14, 2087-2096.
(276) Schoppmann, S.F., Birner, P., Stockl, J., Kalt, R., Ullrich, R., Caucig, C., Kriehuber, E., Nagy, K., Alitalo, K, & Kerjaschki, D. (2002). Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lynphangiogenesis. Am J Pathol. 161, 947-956.
(277) Hamrah, P., Chen, L., Zhang, Q. & Dana, M.R. (2003). Novel expression of vascular endothelial growth factor receptor (VEGFR-3) and VEGF-C on corneal dendrit cells. Am J Pathol. 163, 57-68.
(278) Banerji, S., Ni, J., Wang, S-X., Clasper, S., Su, J., Tammi, R., Jones, M. &
Jackson, D.G. (1999). LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluroran. J Cell Biol. 144, 789-801.
(279) Prevo, R., Banerji, S., Ferguson, D.J., Clasper, S. & Jackson, D.G. (2001). Mouse LYVE-1 is an endocytic receptor for hyaluroran in lymphatic endothelium. J Biol Chem. 276, 19420-19430.
(280) Carreira, C.M., Nasser, S.M., di Tomaso, E., Padera, T.P., Boucher, Y., Tomarev, S.I. & Jain, R.K. (2001). LYVE-1 is not restricted to the lymph vessels: Expression in normal liver blood sinusoids and down-regulation in human liver cancer and cirrhosis. Cancer Res. 61, 8079-8084.
(281) Makinen, T., Adams, R.H., Bailey, J., Lu, Q., Ziemiecki, A., Alitalo, K., Klein, R.
& Wilkinson, G.A. (2005). PDZ interaction site in ephrinB2 is required for the development of the lymphatic system. Mol Cell Biol. 25, 2441-2449.
(282) Jackson, D.G., Prevo, R., Clasper, S & Banerji, S. (2001). LYVE-1, the lymphatic system and tumor lymphangiogenesis. Trends Immunol. 22(6), 317-321.
(283) Abtahian, F., Guerriero, A., Sebzda, E., Lu, M.M., Zhou, R., Mocsai, A., Myers, E.E., Huang, B., Jackson, D.G., Ferrari, V.A., Tybulewicz, V., Lowell, C.A., Lepore, J.J., Koretzky, G.A. & Kahn, M.L. (2003). Regulation of blood and lymphatic vascular separation by signaling proteins SLP-76 and Syk. Science.
299(5604), 247-251.
(284) Yancopoulos, G.D., Davis, S., Gale, N.W., Rudge, J.S., Wiegand, S.J. & Holash, J.
(2000). Vascular-specific growth factors and blood vessel formation. Nature. 407, 242-248.
(285) Gale, N.W., Thurston, G., Hackett, S.F., Renard, R., Wang, Q., McClain, J., Martin, C., Witte, C., Witte, M..H., Jackson, D., Suri, C., Campochiaro, P.A., Wiegand, S.J. & Yancopoulos, G.D. (2002). Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by Angiopoietin-1. Dev Cell. 3, 411-423.
(286) Morisada, T., Oike, Y., Yamada, Y., Urano, T., Akao, M., Kobota, Y., Maekawa, H., Kimura, Y., Ohmura, M., Miyamoto, T., Nozawa, S., Koh, G.Y., Alitalo, K. &
Suda, T. (2005). Angiopoietin-1 promotes LYVE-1-positive lymphatic vessel formation. Blood. 105, 4649-4656.
(287) Tammela, T., Saaristo, A., Lohela, M., Morisada, T., Tornberg, J., Norrmen, C., Oike, Y., Pajusola, K., Thurston, G., Suda, T., Yla-Herttuala, S. & Alitalo, K.
(2005). Angiopoietin-1 promotes lymphatic sprouting and hyperplasia. Blood. 105, 4642-4648.
(288) Poliakov, A., Cotrina, M. & Wilkinson, D.G. (2004). Diverse Roles of Eph Receptors and Ephrins in the Regulation of Cell Migration and Tissue Assembly.
Develop Cell. 7, 465-480.
